立体定向体部放疗与手术治疗可手术早期非小细胞肺癌的成本效果分析
基于两项比较SBRT与VATS肺叶切除术的随机研究生存结果构建Markov模型,从法国支付方视角进行终身分析;SBRT与肺叶切除术总成本分别为9,234.15€和10,726.98€,质量调整生命年分别为16.35和15.80 QALYs;概率敏感性分析显示SBRT具有最高成本效果概率。
要点
- SBRT总成本9,234.15€,肺叶切除术总成本10,726.98€。
- SBRT质量调整生命年16.35 QALYs,肺叶切除术15.80 QALYs。
- 概率敏感性分析显示SBRT相比肺叶切除术具有最高成本效果概率。
核心结论
- 作者认为在可手术早期NSCLC治疗中SBRT优于肺叶切除术。
- 确定性和概率敏感性分析证实该结果稳健,且未被Markov模型构建中的假设所改变。
研究设计与样本
- 基于两项比较SBRT与VATS肺叶切除术治疗早期NSCLC的随机研究的生存结果构建Markov模型。
- 从法国支付方视角进行终身分析,效用值、复发风险和成本取自文献。
- 进行确定性(DSA)和概率性(PSA)敏感性分析以评估所做假设的影响。
主要发现
- 所构建的Markov模型与随机研究汇总分析报告的生存数据一致。
- SBRT与肺叶切除术总成本分别为9,234.15€和10,726.98€。
- SBRT与肺叶切除术质量调整生命年分别为16.35和15.80 QALYs。
- 对所有假设进行的DSA显示增量成本效果比对治疗相关并发症导致的效用减少以及手术和SBRT的初始成本敏感。
- PSA显示SBRT相比肺叶切除术具有最高成本效果概率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Projections estimate an increase of 50% of the incidence of lung cancer by 2030. Early-stage non-small cell lung cancer represented 19% of NSCLC cases diagnosed in the US between 2005 and 2011. There is rising evidence in favour of lung cancer screening, which will reduce the occurrence of later-stage lung cancers while raising the incidence of early-stage NSCLC. Current guidelines state that for early-stage NSCLC, surgical resection should be performed, and stereotactic body radiotherapy (SBRT) is an option for patients who are non-medically operable. In this study, we compared the cost-effectiveness of SBRT with lobectomy in medically operable patients. METHODS: We developed a Markov model based on the survival results of two randomized studies comparing SBRT and video assisted thoracoscopic surgery (VATS) lobectomy in early-stage NSCLC, to describe survival and treatment related complications of patients treated for early-stage NSCLC. This analysis was conducted from the French payer perspective on a lifetime perspective. Utility values, recurrence risks, and costs were adapted from the literature. Deterministic (DSA) and probabilistic (PSA) sensitivity analyses were performed to assess the influence of the assumptions made. RESULTS: The Markov model developed was consistent with survival data reported in the pool analysis of the randomized studies. SBRT and lobectomy total costs were 9,234.15€ and 10,726.98€, respectively, and the quality-adjusted life expectancies were 16.35 and 15.80 QALYs, respectively. The DSA, run on every assumption made, revealed that the incremental cost-effectiveness ratio was mainly sensitive to the decrement of utility caused by treatment related complications and initial cost of both surgery and SBRT. The PSA showed that SBRT had the highest probability of cost-effectiveness compared to lobectomy. CONCLUSIONS: This is the first medico-economic study evaluating SBRT and lobectomy in stage I NSCLC based on randomized studies, and our analyses suggest that SBRT is dominant over lobectomy in operable early-stage NSCLC treatment. Deterministic and probabilistic sensitivity analyses confirmed that this result was robust and that it was not modified by the assumptions made in the Markov model building.
引用
- Paix A, Noel G, Falcoz PE, et al. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Radiother Oncol. 2018. PMID: 29706462. doi:10.1016/j.radonc.2018.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。